Tag: GLP-1 receptor agonists

A new systematic review of 15 studies confirms semaglutide's clinically meaningful weight-loss benefits while cautioning that results vary by dose, ...

A real-world study of 9000 patients with type 2 diabetes in China used cluster analysis to identify three clinical phenotypes ...

A regulator-mandated study using nationwide registry data from Denmark, Sweden and Norway found no increased risk of pancreatic cancer among ...

A new PLOS Medicine Perspective argues that the widening gap between drug efficacy in trials and real-world effectiveness is driven ...

A four-year cohort study found that diabetes care during the COVID-19 pandemic shifted durably toward telemedicine and intensified drug therapy ...

New research presented at the 11th UK Congress on Obesity in Sheffield shows GLP-1 medications are reshaping treatment while behavioural ...

A survey of diverse patients in a Philadelphia health system found that most understand the main uses and side effects ...

A nationally representative Swiss survey finds that 2.5 percent of the population has used GLP-1 receptor agonists, mostly for weight ...

A large real-world study finds that GLP-1 receptor agonists are associated with significantly reduced risks of heart failure, pulmonary hypertension, ...

A pilot randomized trial found that a digital wellness app or medically tailored meals sharply reduced early weight regain after ...

A new study in the Journal of General Internal Medicine examines how manufacturer coupons reshape patient and payer spending across ...

A new review synthesizes molecular, renal and clinical evidence showing that GLP-1 receptor agonists lower systolic blood pressure through converging ...

A Swedish population-based study of adults aged 75 and older with type 2 diabetes finds that advanced chronic kidney disease ...

A new study in Neurocritical Care links GLP-1 receptor agonist use to improved survival in patients undergoing surgery for traumatic ...

A new claims-based study of nearly 4,000 Mississippi Medicaid members finds that adherence to GLP-1 weight-loss drugs plummets within months, ...

A major review argues that the newly renamed polyendocrine metabolic ovarian syndrome is a lifelong systems-level disease driven by hypothalamic, ...

A Mount Sinai retrospective analysis suggests GLP-1 receptor agonists may reduce cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa.

A JAMA cross-sectional study quantifies how frequently commercially insured women in the United States begin GLP-1 receptor agonist prescriptions after ...

A new JAMA Perspective argues that GLP-1 therapies must be embedded in multimodal obesity care combining screening, early management, and ...

Recent advancements in diabetes therapy have taken a significant turn as researchers delve into incretin modulation, revealing its profound potential ...